Llwytho...

Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey

Access to bevacizumab, an important component of oncology treatment regimens, may be limited. This survey of oncologists in the US (n = 150), Europe (n = 230), and emerging markets (EM: Brazil, Mexico, and Turkey; n = 130) examined use of and barriers to accessing bevacizumab as treatment of advance...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Pharmaceuticals (Basel)
Prif Awduron: Monk, Bradley J., Lammers, Philip E., Cartwright, Thomas, Jacobs, Ira
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI 2017
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5374423/
https://ncbi.nlm.nih.gov/pubmed/28134851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph10010019
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!